Medivolve Inc.
MEDVF
$0.002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 105.55% | -52.22% | -98.44% | -98.79% | -116.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.55% | -52.22% | -98.44% | -98.79% | -116.47% |
| Cost of Revenue | 101.38% | -75.32% | -99.54% | -99.55% | -118.96% |
| Gross Profit | 112.56% | -35.39% | -97.42% | -97.97% | -113.48% |
| SG&A Expenses | -50.99% | -72.79% | -72.97% | -75.01% | -70.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.55% | -72.89% | -87.59% | -90.77% | -103.51% |
| Operating Income | 78.65% | 75.06% | -172.32% | -132.03% | -168.06% |
| Income Before Tax | 80.71% | 74.22% | -1,722.63% | -172.39% | -269.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 80.47% | 74.22% | 22.18% | -395.42% | -847.07% |
| Earnings from Discontinued Operations | -44.57% | -86.34% | -30.21% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.05% | 13.54% | -30.47% | -398.08% | -1,095.58% |
| EBIT | 78.65% | 75.06% | -172.32% | -132.03% | -168.06% |
| EBITDA | 78.09% | 75.20% | -155.26% | -122.37% | -149.17% |
| EPS Basic | 29.07% | 13.56% | -26.49% | -382.36% | -192.98% |
| Normalized Basic EPS | 80.87% | 77.22% | -202.44% | -137.07% | -198.77% |
| EPS Diluted | 28.69% | 12.99% | -27.63% | -382.36% | -193.24% |
| Normalized Diluted EPS | 80.87% | 77.22% | -202.44% | -137.07% | -198.77% |
| Average Basic Shares Outstanding | 0.01% | 0.01% | -1.30% | 0.53% | 14.76% |
| Average Diluted Shares Outstanding | 0.01% | 0.01% | -1.30% | 0.53% | 14.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |